View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 29, 2020

Shionogi works on Covid-19 therapies and vaccine

Japanese company Shionogi has partnered with public institutions, academia and other companies to develop potential drugs and vaccine against Covid-19.

Japanese-based Shionogi has partnered with public institutions, academia and other companies to develop potential drugs and vaccine against Covid-19.

The company formed a research alliance with the Hokkaido University Research Center for Zoonosis Control to discover new therapeutic candidates.

They discovered multiple promising lead compounds during in-house in-vitro studies. Shionogi is expediting drug discovery efforts to potentially launch clinical trials later this year.

The company aims to develop effective compounds against Covid-19 infection, which could possibly be a long-lasting outbreak.

Shionogi president and CEO Akira Kato said: “We are not limiting ourselves to the research and development of therapeutic medications, but are also focused on the total care of infectious disease through awareness building, prevention and diagnosis.

“Shionogi will continue to strive to fulfil its social responsibility and to contribute to recovering the safety and security of society by bringing forward new tools and technologies for the treatment of Covid-19.”

Meanwhile, Shionogi group company UMN Pharma is leveraging its Baculovirus Expression Vector System technology to identify and create a recombinant protein vaccine for Covid-19.

Started in March, the vaccine development programme is supported by the Japan Agency for Medical Research and Development (AMED).

The company intends to begin clinical trials in Japan this year.

Shionogi is focused on developing anti-infectives for various diseases.

The company recently introduced Fetroja (cefiderocol) in the US to treat complicated urinary tract infections, including pyelonephritis, caused by gram-negative microorganisms.

Fetroja is indicated for patients aged 18 years or above with limited or no alternative treatment options.

Cefiderocol also holds approval in the European Union (EU) for infections caused by aerobic gram-negative bacteria in people aged 18 years or older with limited treatment options.

In December, Shionogi’s thrombocytopenia drug secured approval for use on NHS.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU